Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer

Histopathology

Volumn 61, Issue 6, 2012, Pages 1089-1105

  Mascolo, Massimo ^a   Ilardi, Gennaro ^a   Romano, Maria Fiammetta ^a   Celetti, Angela ^a   Siano, Maria ^a   Romano, Simona ^a   Luise, Chiara ^a   Merolla, Francesco ^a   Rocco, Alba ^a   Vecchione, Maria Luisa ^a   De Rosa, Gaetano ^a   Staibano, Stefania ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CAF 1 p60; Oral cancer; PARP 1; Prognosis; Stem cells

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD133 ANTIGEN; CD44V6 ANTIGEN; CHROMATIN ASSEMBLY FACTOR 1; CHROMATIN ASSEMBLY FACTOR 1 P60; HERMES ANTIGEN; NESTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PARAFFIN; PROTEIN HYDROLYSATE; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VIRUS TYPING; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHROMATIN ASSEMBLY FACTOR-1; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NERVE TISSUE PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

HUMAN PAPILLOMAVIRUS;

EID: 84870392794     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04313.x     Document Type: Article

References (94)

1. Deshpande AM, Wong DT. Molecular mechanisms of head and neck cancer. Expert Rev. Anticancer Ther. 2008; 8; 799-809.
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60; 277-300.
3. Mydlarz WK, Hennessey PT, Califano JA. Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin. Med. Diagn. 2010; 4; 53-65.
4. Schuller DE, Wilson HE, Smith RE, Batley F, James AD. Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer 1983; 51; 15-19.
5. Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit. Rev. Oncol. Hematol. 1983; 1; 323-355.
6. Monroe MM, Anderson EC, Clayburgh DR, Wong MH. Cancer stem cells in head and neck squamous cell carcinoma. J. Oncol. 2011; 2011; 762-780.
7. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444; 756-760.
8. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin. Cancer Res. 2009; 15; 5145-5153.
9. Hong SP, Wen J, Bang S, Park S, Song SY. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009; 125; 2323-2331.
10. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl Cancer Inst. 2006; 98; 1755-1757.
11. Bertolini G, Roz L, Perego P et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 2009; 106; 16281-16286.
12. Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75; 1216-1225.
13. Alison MR, Lim SML, Nicholson LJ. Cancer stem cells: problems for therapy?J. Pathol. 2011; 223; 147-161.
14. Oliveira LR, Oliveira-Costa JP, Araujo IM et al. Cancer stem cell immunophenotypes in OSCC. J. Oral Pathol. Med. 2010; 40; 135-142.
15. Zhou ZT, Jiang WW. Cancer stem cell model in OSCC. Curr. Stem Cell Res. Ther. 2008; 3; 17-20.
16. Plummer R, Jones C, Middleton M et al. Phase I study of the poly(ADP-ribose) inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2008; 14; 7917-7923.
17. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr. Opin. Pharmacol. 2006; 6; 364-368.
18. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 1999; 342; 249-268.
19. McDaid JR, Loughery J, Dunne P et al. MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea. Br. J. Cancer 2009; 101; 441-451.
20. Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem. Cell Biol. 2005; 83; 354-364.
21. Rouleau M, Aubin RA, Poirier GG. Poly(ADP-ribosyl)ated chromatin domains: access granted. J. Cell Sci. 2004; 117; 815-825.
22. Shim KS, Bergelson JM, Furuse M, Ovod V, Krude T, Lubec G. Reduction of chromatin assembly factor 1 p60 and C21orf2 protein, encoded on chromosome 21, in Down syndrome brain. J. Neural Transm. Suppl. 2003; 67; 117-128.
23. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009; 459; 113-117.
24. Li Q, Huang Y, Xiao N, Murray V, Chen J, Wang J. Real time investigation of protein folding, structure, and dynamics in living cells. Methods Cell Biol. 2008; 90; 287-325.
25. Chen CC, Tyler J. Chromatin reassembly signals the end of DNA repair. Cell Cycle 2008; 7; 3792-3797.
26. Kadyrova LY, Blanko ER, Kadyrov FA. CAF-I-dependent control of degradation of the discontinuous strands during mismatch repair. Proc. Natl. Acad. Sci. USA 2011; 108; 2753-2758.
27. Kim JA, Haber JE. Chromatin assembly factors Asf1 and CAF-1 have overlapping roles in deactivating the DNA damage checkpoint when DNA repair is complete. Proc. Natl. Acad. Sci. USA 2009; 106; 1151-1156.
28. Takami Y, Ono T, Fukagawa T, Shibahara K, Nakayama T. Essential role of chromatin assembly factor-1-mediated rapid nucleosome assembly for DNA replication and cell division in vertebrate cells. Mol. Biol. Cell 2007; 18; 129-141.
29. Nabatiyan A, Krude T. Silencing of chromatin assembly factor 1 in human cells leads to cell death and loss of chromatin assembly during DNA synthesis. Mol. Cell. Biol. 2004; 24; 2853-2862.
30. Hoek M, Stillman B. Chromatin assembly factor 1 is essential and couples chromatin assembly to DNA replication invivo. Proc. Natl. Acad. Sci. USA 2003; 100; 12183-12188.
31. Polo SE, Theocharis SE, Grandin L et al. Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours. Histopathology 2010; 57; 716-724.
32. Staibano S, Mascolo M, Rocco A et al. The proliferation marker chromatin assembly factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours. Oncol. Rep. 2011; 25; 13-22.
33. Staibano S, Mascolo M, Mancini FP et al. Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer. Histopathology 2009; 54; 580-589.
34. Staibano S, Mignogna C, Lo Muzio L et al. Chromatin assembly factor-1 (CAF-1)-mediated regulation of cell proliferation and DNA repair: a link with the biological behaviour of squamous cell carcinoma of the tongue?Histopathology 2007; 50; 911-919.
35. Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors?Cancer Treat. Rev. 2009; 35; 403-408.
36. Gillison ML. HPV and prognosis for patients with oropharynx cancer. Eur. J. Cancer 2009; 45; 383-385.
37. Gillison M. HPV and its effect on head and neck cancer prognosis. Clin. Adv. Hematol. Oncol. 2010; 8; 680-682.
38. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst. 2008; 100; 407-420.
39. Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 2008; 26; 3128-3137.
40. Jung AC, Briolat J, Millon R et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int. J. Cancer 2010; 126; 1882-1894.
41. Snow A, Laudadio J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv. Anat. Pathol. 2010; 17; 394-403.
42. Hoffmann M, Ihloff AS, Görögh T et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int. J. Cancer 2010; 127; 1595-1602.
43. Singhi AD, Westra WH. Comparison of human papillomavirus insitu hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116; 2166-2173.
44. American Joint Committee on Cancer. AJCC cancer staging manual, 7th edn. New York: Springer, 2009; 49-61.
45. Wang SL, Yang CH, Chen HH, Chai CY. A simple and economical method for the manual construction of well-aligned tissue arrays. Pathol. Res. Pract. 2006; 202; 485-486.
46. Oliveira-Costa JP, Zanetti JS, Silveira GG et al. Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas. Diagn. Pathol. 2011; 6; 73-81.
47. Polo SE, Theocharis SE, Klijanienko J et al. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res. 2004; 64; 2371-2381.
48. Staibano S, Pepe S, Lo Muzio L et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol. 2005; 36; 724-731.
49. Volgareva G, Zavalishina L, Andreeva Y et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004; 4; 58-68.
50. Ordi J, Garcia S, del Pino M et al. p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. Int. J. Gynecol. Pathol. 2009; 28; 90-97.
51. Sabol I, Salakova M, Smahelova J et al. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J. Clin. Microbiol. 2008; 46; 1606-1613.
52. Tan SE, Garland SM, Rumbold AR, Tabrizi SN. Human papillomavirus genotyping using archival vulval dysplastic or neoplastic biopsy tissues: comparison between the INNO-LiPA and linear array assays. J. Clin. Microbiol. 2010; 48; 1458-1460.
53. Celetti A, Testa D, Staibano S et al. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin. Cancer Res. 2005; 11; 8019-8027.
54. Romano S, D'Angelillo A, Pacelli R et al. Role of FK506 binding protein 51 (FKBP51) in the control of apoptosis of irradiated melanoma cells. Cell Death Differ. 2010; 17; 145-157.
55. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1997; 33; 159-174.
56. Costea DE, Tsinkalovsky O, Vintermyr OK, Johannessen AC, Mackenzie IC. Cancer stem cells-new and potentially important targets for the therapy of OSCC. Oral Dis. 2006; 12; 443-454.
57. Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005; 96; 1219-1223.
58. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004; 101; 14228-14233.
59. Pollard SM, Yoshikawa K, Clarke ID et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4; 568-580.
60. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197; 461-463.
61. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414; 105-111.
62. Tabor MP, Brakenhoff RH, van Houten VM et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 2001; 7; 1523-1532.
63. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138; 645-659.
64. Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br. J. Cancer 2010; 103; 439-445.
65. Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett. 1981; 14; 227-236.
66. Alderson T. New targets for cancer chemotherapy-poly(ADP-ribosylation) processing and polyisoprene metabolism. Biol. Rev. Camb. Philos. Soc. 1990; 65; 623-641.
67. Berger NA, Adams JW, Sikorski GW, Petzold SJ, Shearer WT. Synthesis of DNA and poly(adenosine diphosphate ribose) in normal and chronic lymphocytic leukemia lymphocytes. J. Clin. Invest. 1978; 62; 111-118.
68. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 1983; 43; 3441-3446.
69. Khan K, Araki K, Wang D et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010; 32; 381-391.
70. Helmbach H, Kern MA, Rossmann E et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J. Invest. Dermatol. 2002; 118; 923-932.
71. Virág L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr. Vasc. Pharmacol. 2005; 3; 209-214.
72. Tang L, Tron VA, Reed JC et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin. Cancer Res. 1998; 4; 1865-1871.
73. Decker P, Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr. Pharm. Biotechnol. 2002; 3; 275-283.
74. Bürkle A, Brabeck C, Diefenbach J, Beneke S. The emerging role of poly(ADP-ribose) polymerase-1 in longevity. Int. J. Biochem. Cell Biol. 2005; 37; 1043-1053.
75. Rojo F, García-Parra J, Zazo S et al. Nuclear PARP-protein overexpression is associated with poor overall survival in early breast cancer. Ann. Oncol. 2011; 23; 1156-1164.
76. Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int. J. Gynecol. Pathol. 2007; 26; 147-153.
77. Bouda M, Gorgoulis VG, Kastrinakis NG et al. 'High risk' HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod. Pathol. 2000; 13; 644-653.
78. Sugiyama M, Bhawal UK, Dohmen T, Ono S, Miyauchi M, Ishikawa T. Detection of human papillomavirus-16 and HPV-18 DNA in normal, dysplastic, and malignant oral epithelium. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003; 95; 594-600.
79. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007; 356; 1944-1956.
80. Luo CW, Roan CH, Liu CJ. Human papillomaviruses in oral squamous cell carcinoma and pre-cancerous lesions detected by PCR-based gene-chip array. Int. J. Oral Maxillofac. Surg. 2007; 36; 153-158.
81. Chow LT, Broker TR, Steinberg BM. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010; 118; 422-449.
82. Allam JP, Erdsach T, Wenghoefer M, Bieber T, Appel TR, Novak N. Successful treatment of extensive human papillomavirus-associated oral leucoplakia with imiquimod. Br. J. Dermatol. 2008; 158; 644-646.
83. Varnai AD, Bollmann M, Bankfalvi A et al. The prevalence and distribution of human papillomavirus genotypes in oral epithelial hyperplasia: proposal of a concept. J. Oral Pathol. Med. 2009; 38; 181-187.
84. Worden FP, Kumar B, Lee JS et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J. Clin. Oncol. 2008; 26; 3138-3146.
85. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996; 56; 4620-4624.
86. Iwasaki I, Suda T. Cancer stem cells and their niche. Cancer Sci. 2009; 100; 1166-1172.
87. Heck JE, Barthiller J, Vaccarella S et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int. J. Epidemiol. 2010; 39; 166-181.
88. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009; 27; 1992-1998.
89. Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic. Biol. Med. 2009; 47; 13-26.
90. Soldatenkov VA, Smulson M. Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. Int. J. Cancer 2000; 90; 59-67.
91. Szabo C, Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. 1998; 19; 287-298.
92. Saini V, Shoemaker RH. Potential for therapeutic targeting of tumor stem cells. Cancer Sci. 2010; 101; 16-21.
93. Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141; 69-80.
94. Kirkegaard T, Edwards J, Tovey S et al. Observer variation in immunohistochemical analysis of protein expression, time for a change?Histopathology 2006; 48; 787-794.